Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 4, 2007, Pages 403-410

  Harris, Lucinda A ^a   Crowell, Michael D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANYLATE CYCLASE ACTIVATOR; INDOMETACIN; LINACLOTIDE; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IRRITABLE COLON; LOOSE FECES; NONHUMAN; REVIEW; TREATMENT OUTCOME;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CONSTIPATION; HUMANS; IRRITABLE BOWEL SYNDROME; MOLECULAR STRUCTURE; PEPTIDES;

EID: 34547868470     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. 538371 Activation of intestinal epithelial surface receptors as a novel approach for the treatment of c-IBS and chronic constipation. Cordero E, Driggers E, Kessler M, Lai S, Norman T, Pierce C, Reza T, Tobin JV, Mahajan-Miklos S, Currie M GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs 746
2. 539427 Microbia presents data on novel drug candidate with potential to treat irritable bowel syndrome. Microbia Inc PRESS RELEASE 2004 May 19
3. 540043 Digestive Disease Week (Part IV), New Orleans, 15-20 May 2004. Gotham S IDDB MEETING REPORT 2004 May 15-20
4. 601975 Microbia's MD-1100 safe in phase Ia IBS trial. Microbia Inc PRESS RELEASE 2005 May 17
5. 631339 Microbia presents results from phase 1 trial demonstrating MD-1100 is active and well-tolerated in healthy volunteers. Microbia Inc PRESS RELEASE 2005 October 31
6. 640312 EuroTIDES 2005 - Sixth Annual IBC Conference (Part I), Oligonucleotide, RNAi and peptides for the drug development and manufacturing industry, Munich, Germany. Kelland L IDDB MEETING REPORT 2005 December 05-07
7. 652411 Microbia raises $75 million in private equity financing to advance therapeutic candidates through clinical trials. Microbia Inc PRESS RELEASE 2006 February 27
8. 667285 Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Kurtz C, Fitch D, Busby RW, Fretzen A, Geis G, Currie MG GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs 132
9. 668672 Influence of guanylate cyclase C binding ligand MD-1100 on TNBSinduced visceral hypersensitivity in WT vs KO guanylate cyclase C deficient mice. Eutamene H, Theodorou V, Tondereau V, Waget A, Fioramonti J, Bryant AP, Bueno L GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs T2031
10. 668673 The characterization of an active metabolite of MD-1100, a therapeutic agent in development for the treatment of IBS-C and chronic constipation. Bryant AP, Busby RW, Cordero EA, Kessler MM, Pierce CM, Tobin JV, Fretzen A, Kurtz C, Currie MG GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs T2034
11. 749262 The molecular target of MD-1100 is guanylate cyclase-C (GC-C), an apical receptor on intestinal epithelial cell. Busby RW, Bryant AP, Cordero EA, Kessler MM, Pierce CM, Tobin JV, Cohen MB, Currie MG GASTROENTEROLOGY 2005 128 4 Suppl 2 A464
12. 749263 MD-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Bryant AP, Busby RW, Cordero EA, Tobin JV, Bartolini WP, Beaufrand C, Bueno L, Currie MG GASTROENTEROLOGY 2005 128 4 Suppl 2 A464
13. 749264 Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Currie MG, Kurtz C, Mahajan-Miklos S, Busby RW, Fretzen A, Geis S AM J GASTROENTEROL 2005 100 9 S328
14. 749265 Antinociceptive actions of MD-1100, a novel therapeutic agent for c-IBS, in animal models of visceral pain. Bueno L, Beaufrand C, Mahajan-Miklos S, Bryant AP, Currie MG AM J GASTROENTEROL 2004 99 10 s283
15. 776420 AGA technical review on irritable bowel syndrome. Drossman DA, Camilleri M, Mayer EA, Whitehead WE GASTROENTEROLOGY 2002 123 6 2108-2131
16. 776446 Epidemiology of constipation in North America: A systematic review. Higgins PD, Johanson JF AM J GASTROENTEROL 2004 99 4 750-759
17. 776448 Emerging drugs for irritable bowel syndrome. Bradesi S, Tillisch K, Mayer E EXPERT OPIN EMERGING DRUGS 2006 11 2 293-313
18. 776450 Irritable bowel syndrome and chronic constipation: Emerging drugs, devices and surgical treatments. Harris LA, Hansel S, DiBaise J, Crowell MD CURR GASTROENTEROL REP 2006 8 4 282-290
19. 776453 The usual medical care for irritable bowel syndrome. Whitehead WE, Levy RL, Von Korff M, Feld AD, Palsson OS, Turner M, Drossman DA ALIMENT PHARMACOL THER 2004 20 11-12 1305-1315
20. 776460 An internet-based survey of the prevalence and symptom spectrum of chronic constipation. Schiller LR, Dennis E, Toth G AM J GASTROENTEROL 2004 99 Suppl S234 Abs 723
21. 776463 Protein kinase C regulates transcription of the human guanylate cyclase C gene. Roy N, Guruprasad MR, Kondaiah P, Mann EA, Giannella RA, Visweswariah SS EUR J BIOCHEM 2001 268 7 2160-2171
22. 776465 Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. Schulz S, Lopez MJ, Kuhn M, Garbers DL J CLIN INVEST 1997 100 6 1590-1595
23. 776467 Linaclotide significantly improves post-operative ileus and opiate-induced constipation in rats. Bryant AP, Cordero EA, Tobin JV, Rivers S, Kurtz CB, Currie MG AM J GASTROENT 2006 101 9 S486 A1257
24. 776468 An office guide to whole gut transit time. Patient's recollection of their stool form. Heaton KW, O'Donnell LJ J CLIN GASTROENTEROL 1994 19 1 28-30
25. 781897 GSK and Adolor announce preliminary results from phase 3 safety study of Alvimopan (ENTEREG/ENTRAREG). GlaxoSmithKline plc PRESS RELEASE 2007 April 05
26. 795308 FDA Public Health Advisory: Tegaserod maleate (marketed as Zelnorm). US Food and Drug Administration INTERNET SITE 2007 March 30
27. 795523 Effects of a novel, first-in-class guanylate cyclase-C activator, linaclotide acetate (MD-1100), on gastrointestinal and colonic transit and bowel habits in patients with constipation-predominant irritable bowel syndrome (C-IBS). Andresen V, Busciglio I, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Zinsmeister AR, Currie MG, Kurtz C, Camilleri M DIG DIS WEEK 2007 Abs 532
28. 799588 Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea. Zhang W, Mannan I, Schulz S, Parkinson SJ, Alekseev AE, Gomez LA, Terzic A, Waldman SA FASEB J 1999 13 8 913-922
29. 799611 Linaclotide shown to improve symptoms of chronic constipation in phase 2A study. Microbia Inc PRESS RELEASE 2006 October 24
30. 799614 Microbia: Creating and developing innovative human medicines. Microbia Inc COMPANY WORLD WIDE WEB SITE 2007 May 29
31. 799737 MM-419447 is an active in vivo metabolite of linaclotide, a therapeutic agent in development for the treatment of IBS-C and chronic constipation. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Kessler MM, Pierce CM DRUG METAB REV 2006 38 Suppl 2 96-97
32. 800465 Microbia announces positive phase 2 results for its investigational compound linaclotide. Microbia Inc PRESS RELEASE 2007 May 21
33. 800469 Cellular effects of guanylin and uroguanylin. Sindic A, Schlatter E J AM SOC NEPHROL 2006 17 3 607-616